Wednesday 17 January 2018 ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Cloudtag Inc – can it protect its “leading edge” technology from rivals?

By Tom Winnifrith | Wednesday 14 December 2016

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

A key plank in the case for the value inherent in Cloudtag (CTAG) made by Bulletin Board Morons led by the ramper in Chief, Liam Nicholas, is the self-proclaimed leading edge medical grade technology behind the Cloudtag product. I am rather less sure that the liars have such a product but to humour the morons...

As with all technological developments, if a genuine leading edge development is invented, rivals will seek to replicate the new features if they can. Disputes have occurred between tech giants such as Apple and Samsung over design features and corporate disputes often occur over patents especially in new and rapidly growing markets.

So does Cloudtag have the legal protection to protect its technological developments from being copied. Sadly not because as the attached extract HERE from the UKs Intellectual Patent Office shows Cloudtag patents are only pending approval.

This matters because until such time as the patents are approved any bigger rival could if it wanted get hold of the Cloudtag product when it launches and seek to utilize the ideas without Cloudtag having the ability to sue (as this extract from a patent expert indicates) until such time as the patent is granted by when it may be too late for Cloudtag.

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on CTAG


Comments are turned off for this article.

Site by Everywhen